Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Ltd published its unaudited standalone financial results for the quarter ended 31 December 2025 in Free Press (English) and Choutha Sansar (Hindi) on 10 February 2026, as required under SEBI LODR Regulation 47. Total revenue from operations fell to Rs 384.04 lakhs, down about 29% from Rs 540.27 lakhs in the same quarter last year. The company swung to a pre-tax loss of Rs 60.78 lakhs versus a profit of Rs 16.05 lakhs in Q3 FY25, and a net loss after tax of Rs 16.77 lakhs (vs a profit of Rs 5.22 lakhs YoY). Basic and diluted EPS came in at -Rs 0.33, compared with Rs 0.10 in the year-ago quarter. Reference figures for the year ended 31 March 2025 show revenue of Rs 2,255.48 lakhs, net profit of Rs 57.88 lakhs, paid-up equity of Rs 534.83 lakhs and reserves of Rs 382.96 lakhs.
Weak quarterly performance — a sharp revenue decline and a swing to a loss — is negative for short-term sentiment, though the loss size is small relative to the company's equity base (reserves of Rs 421.01 lakhs). Shareholders should watch whether the Q3 weakness is a one-off or signals a sustained slowdown in the core business.